Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286208 | 1.00 | KCNJ1 (0.55) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL30444525 | 1.00 | KCNJ1 (0.55) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2891319 | 1.00 | KCNJ1 (0.55) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL30444657 | 1.00 | KCNJ1 (0.55) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17977100 | 0.88 | KCNJ1 (0.58) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL30751857 | 0.87 | KCNJ1 (0.53) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17303429 | 0.83 | KCNJ1 (0.48) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286511 | 0.83 | KCNJ1 (0.43) | KCNJ1 | |
| SCHEMBL286415 | 0.83 | KCNJ1 (0.43) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14726343 | 0.83 | KCNJ1 (0.43) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231802-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-05-05 | — | — | EP | claimed |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-10-15 | — | — | US | claimed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | claimed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | claimed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | claimed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3083573-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013028474-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885KCNH2 382/4885ACHE 3686/4885 |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | CPS1, PDXK, SDHA | KCNJ1 2381/4885KCNH2 1134/4885ACHE 1181/4885 |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | CPS1, PDXK, SDHA | KCNJ1 2381/4885KCNH2 1134/4885ACHE 1181/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | KCNJ1 7/4885KCNH2 15/4885ACHE 4183/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.